Loading...
Loading...
BPTS| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 0.0K |
| Gross Profit | 0.0K |
| Operating Expense | 2,195.0K |
| Operating I/L | -2,195.0K |
| Other Income/Expense | -713.5K |
| Interest Income | 0.0K |
| Pretax | -2,908.5K |
| Income Tax Expense | -2.5K |
| Net Income/Loss | -2,906.0K |
Biophytis S.A. is a clinical-stage biotechnology company specializing in developing therapeutics for age-related diseases. Its lead drug candidate, Sarconeos (BIO101), is an orally administered small molecule targeting neuromuscular diseases such as sarcopenia and Duchenne muscular dystrophy, as well as severe respiratory failure in COVID-19 patients. The company also develops Macuneos (BIO201) for retinal diseases. Biophytis SA generates revenue through the development and commercialization of its therapeutic products, as well as through collaboration agreements with organizations like AFM-Telethon for the advancement of its drug candidates.
